Cancer diagnoses tended to arise more in patients who bled on oral anticoagulants (OACs), a Canadian population-based cohort ...

Background Anticoagulation therapy reduces stroke risk in patients with atrial fibrillation (AF), but it is often underused ...

A new study suggests that the benefits of prescribing anticoagulation drugs to certain older people outweigh the potential risks.

oral vitamin K antagonists remain the cornerstone of anticoagulation for long-term treatment or secondary prevention. Much of the research in optimizing anticoagulant therapy for acute VTE has ...

Original Research on Real-World Outcomes of Anticoagulation and Corticosteroid in COVID-19,” published in the February 2025 ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Promising results show that abelacimab could revolutionize anticoagulation therapy by slashing bleeding risks without compromising stroke protection for patients with atrial fibrillation.

When an older adult with atrial fibrillation, or Afib, stops taking an anticoagulant, it raises their risk of stroke or heart attack more than risks of bleeding, according to a new report published ...